Study monitoring is the independent scientific and regulatory oversight of outsourced GLP toxicology and other non-clinical studies conducted by contract research organizations (CROs). It provides sponsors with independent oversight to support studies that are planned, conducted, documented, and reported in accordance with Good Laboratory Practice (GLP), OECD Test Guidelines, and other applicable regulatory requirements.

Effective study monitoring helps sponsors maintain visibility and control throughout the study lifecycle while identifying scientific, operational, and regulatory risks at an early stage.

Study monitoring typically includes:

• Assessment of study design and regulatory expectations
• Review of study protocols and protocol amendments
• Oversight of CRO study conduct and project milestones
• Review of protocol deviations, investigations, and corrective actions
• Assessment of study data, documentation, and final reports
• Coordination and communication between the sponsor and the CRO

The objective of study monitoring is to support the generation of reliable, traceable, scientifically robust data that are suitable for regulatory evaluation, submission, and decision-making.

An independent study monitor acts on behalf of the sponsor to provide scientific and regulatory oversight of outsourced GLP toxicology and other non-clinical studies. While the CRO conducts the study, the study monitor independently reviews study progress, identifies potential risks, evaluates critical study outputs, and supports informed sponsor decision-making throughout the project lifecycle.

The study monitor does not replace the CRO, the Study Director, or the sponsor's regulatory responsibilities. Instead, the monitor provides objective oversight to help ensure that studies remain scientifically robust, compliant with applicable regulatory requirements and quality expectations, and aligned with the sponsor's objectives.

Typical responsibilities include:

• Reviewing study protocols and protocol amendments
• Assessing CRO proposals, capabilities, and study feasibility
• Monitoring study progress, milestones, and timelines
• Evaluating protocol deviations, investigations, and corrective actions
• Reviewing interim data, study documentation, and quality records
• Assessing draft and final study reports
• Facilitating communication between the sponsor and the CRO
• Identifying scientific, operational, and regulatory risks throughout the study lifecycle

Independent study monitoring supports high-quality study execution while helping sponsors maintain oversight of outsourced studies without becoming involved in routine study operations.

Regulatory authorities evaluate whether toxicology study data are reliable, scientifically interpretable, adequately documented, and generated in accordance with applicable regulatory requirements. When these expectations are not met, regulators may question the reliability of the data or determine that the study is not suitable to support regulatory decision-making.

Common reasons include:

• Non-compliance with Good Laboratory Practice (GLP)
• Significant protocol deviations that affect study validity
• Inadequate study design or inappropriate test methods
• Poor characterization of the test item or insufficient analytical support
• Data integrity concerns or incomplete raw data documentation
• Inadequate documentation of study procedures or quality records
• Failure to follow applicable OECD, ICH, VICH, ISO, or other relevant regulatory guidelines
• Incomplete, inconsistent, or poorly documented study reports
• Insufficient scientific justification for study interpretation or conclusions

Early study planning, careful CRO selection, and independent study monitoring help identify and address these issues before they affect regulatory submissions, reducing the likelihood of regulatory questions, study delays, or repeat studies.

Within the lifecycle of a GLP toxicology or other non-clinical study, the sponsor, contract research organization (CRO), and independent study monitor each have distinct but complementary responsibilities.

The sponsor initiates and funds the study, defines the study objectives, selects the CRO, and remains responsible for the quality, integrity, and regulatory use of the study data. Although study activities may be outsourced, regulatory responsibility for the study cannot be outsourced.

The CRO performs the study according to the approved protocol and applicable regulatory requirements. The CRO generates the study data, maintains the study records, and prepares the study documentation and final reports.

The independent study monitor does not conduct the study or assume the sponsor's regulatory responsibilities. Instead, the study monitor provides independent scientific and regulatory oversight on behalf of the sponsor by reviewing study conduct, evaluating study quality, identifying potential risks, and assessing whether the study remains scientifically robust and suitable for its intended regulatory purpose.

In summary:

• The sponsor commissions the study and retains responsibility for the regulatory acceptability of the study data.
• The CRO conducts the study and generates the scientific data and study reports.
• The independent study monitor provides objective oversight of the outsourced study and supports the sponsor through independent scientific and regulatory review.

Independent study monitoring provides sponsors with greater visibility into outsourced studies, facilitates informed decision-making, and supports the delivery of high-quality data suitable for regulatory submission.

Insufficient oversight can increase scientific, operational, financial, and regulatory risks throughout outsourced GLP toxicology and other non-clinical studies. Without effective oversight, study issues may remain undetected until late in the project, when corrective actions are more complex, costly, and time-consuming.

Potential consequences include:

• Significant protocol deviations
• Failure to meet GLP or other applicable regulatory requirements
• Data quality or data integrity issues
• Delays in study completion or reporting
• Budget overruns and increased project costs
• Repeat studies or additional experimental work
• Increased regulatory questions or requests for clarification
• Reduced confidence in study conclusions
• Delays to regulatory submissions or product development timelines
• Unnecessary animal use resulting from avoidable study deficiencies

Many of these risks can be identified and managed more effectively when they are detected early in the study lifecycle through independent scientific and regulatory oversight.

Organizations outsourcing GLP toxicology and other non-clinical studies often use independent study monitors to maintain scientific oversight, regulatory compliance, and visibility throughout the project lifecycle. Independent monitoring is particularly valuable when sponsors have limited internal toxicology expertise, are managing multiple CROs, or are conducting complex studies with significant regulatory implications.

An independent study monitor can help sponsors:

• Evaluate CRO performance and study quality
• Review study protocols, amendments, and key study deliverables
• Support timely scientific and regulatory decision-making
• Identify study risks before they affect project outcomes
• Assess protocol deviations and corrective actions
• Improve communication between sponsors and CROs
• Monitor project progress, timelines, and critical milestones
• Support preparation for regulatory submissions

Independent study monitoring is particularly valuable for pharmaceutical companies, biotechnology companies, veterinary medicine developers, medical device manufacturers, chemical companies, and other organizations that rely on outsourced GLP studies to support regulatory submissions.

By providing independent scientific and regulatory oversight, study monitoring helps sponsors retain visibility and control over outsourced studies while improving study quality, reducing regulatory risk, and supporting successful project outcomes.

Study monitoring does not replace regulatory review; however, it helps ensure that GLP toxicology and other non-clinical studies generate high-quality, well-documented data that meet applicable scientific and regulatory expectations.

Regulatory authorities expect studies to be scientifically robust, conducted according to approved protocols, and supported by complete, accurate, and traceable documentation. Independent study monitoring contributes to these expectations by identifying potential issues early and promoting consistent study oversight throughout the project lifecycle.

Study monitoring supports regulatory acceptance by contributing to:

• Scientifically appropriate study design
• Compliance with GLP and applicable regulatory guidelines
• Complete, accurate, and traceable study documentation
• Timely identification and assessment of protocol deviations
• Consistent reporting and data interpretation
• Regulatory submission readiness

By strengthening study quality, documentation, and regulatory compliance, independent study monitoring helps reduce the likelihood of regulatory questions and supports efficient evaluation of study data during regulatory review.

An independent study monitor should ideally be involved before CRO selection and before study initiation. Early involvement allows scientific, operational, and regulatory considerations to be incorporated into study planning before key project decisions have been made.

Early involvement enables the study monitor to:

• Review study objectives and regulatory requirements
• Support study design and protocol development
• Evaluate and compare CRO proposals
• Support CRO qualification and selection
• Establish an appropriate monitoring strategy
• Assess project timelines, budgets, and study feasibility
• Identify scientific, operational, and regulatory risks
• Monitor critical study milestones during study conduct
• Review draft and final study reports before completion

Although study monitoring can provide value at any stage of a project, involvement during the planning phase offers the greatest opportunity to identify risks early, support informed decision-making, and reduce the likelihood of costly delays or repeat studies.

An independent toxicology study monitor should combine a strong scientific background with practical experience overseeing outsourced GLP toxicology and other non-clinical studies. Effective study monitoring requires not only technical expertise but also a thorough understanding of regulatory requirements, CRO operations, study management, and regulatory submissions.

In addition to scientific knowledge, experienced study monitors should be able to critically evaluate study execution, identify emerging scientific and regulatory risks, communicate effectively with sponsors and CROs, and assess whether study activities remain aligned with study objectives and applicable regulatory requirements throughout the project lifecycle.

Important qualifications and competencies include:

• Expertise in toxicology, pharmacology, regulatory science, or a related discipline
• Thorough knowledge of Good Laboratory Practice (GLP)
• Familiarity with OECD, ICH, VICH, ISO, and other applicable regulatory guidelines
• Experience managing or monitoring outsourced non-clinical studies
• Understanding of regulatory submissions and regulatory data requirements
• Ability to critically evaluate study design, protocol deviations, study documentation, and final reports
• Strong project management, communication, and problem-solving skills

Professional certifications, such as European Registered Toxicologist (ERT) or Diplomate of the American Board of Toxicology (DABT), may provide additional assurance of professional competence. Although these certifications are not mandatory for study monitoring, they demonstrate recognized expertise in toxicology and a commitment to maintaining high professional standards.

Sponsors should seek independent study monitors who combine scientific expertise, practical experience, and regulatory knowledge to help ensure that outsourced studies are scientifically robust, compliant with applicable requirements, and suitable for their intended regulatory purpose.

Selecting and qualifying a contract research organization (CRO) for a GLP toxicology study requires a structured assessment of scientific capability, regulatory compliance, quality systems, and operational reliability. The objective is to identify a CRO that can generate scientifically robust, GLP-compliant data suitable for regulatory evaluation and submission.

CRO selection should consider the specific study objectives, product type, regulatory pathway, and level of scientific expertise required. Key evaluation criteria include:

• Demonstrated compliance with Good Laboratory Practice (GLP)
• Experience conducting relevant toxicology studies and comparable study types
• Scientific expertise in the applicable toxicology area
• Quality management systems and data integrity processes
• Inspection history and regulatory track record
• Availability of appropriate facilities, equipment, and qualified personnel
• Study timelines, capacity, and resource allocation
• Quality of scientific communication, documentation, and reporting

CRO selection should not be based on cost alone. The most appropriate CRO is the one that provides the best overall combination of scientific expertise, regulatory compliance, study quality, and operational reliability for the specific development program.

Independent study monitoring can support CRO selection by providing objective evaluation of CRO proposals, identifying potential risks, and helping sponsors make informed outsourcing decisions before study initiation.

Toxicology study monitoring is performed within the framework of applicable regulatory guidelines and quality standards relevant to the product type, study objective, and intended regulatory submission.

Independent study monitors support studies conducted according to internationally recognized requirements, including:

• Good Laboratory Practice (GLP)
• OECD Test Guidelines
• International Council for Harmonisation (ICH) guidelines
• Veterinary International Cooperation on Harmonisation (VICH) guidelines
• ISO standards, including ISO 10993 for medical device biological evaluation
• Sector-specific regulatory requirements applicable to pharmaceuticals, veterinary products, chemicals, cosmetics, and food/feed products

The specific requirements applied to a toxicology study depend on the regulatory pathway and development context. Independent study monitoring helps sponsors interpret applicable expectations, evaluate study compliance, and identify potential regulatory risks throughout the study lifecycle.

Independent study monitoring can provide value across a broad range of outsourced toxicology and non-clinical studies, particularly when studies are complex, regulatory-critical, or conducted by external CRO partners.

Agirad provides scientific and regulatory oversight for studies including:

• Acute and repeated-dose toxicity studies
• Skin and eye irritation studies
• Skin sensitisation studies
• Genotoxicity studies
• Carcinogenicity studies
• Developmental and reproductive toxicity (DART) studies
• Extractables and leachables (E&L) studies
• Biocompatibility studies
• Bioanalysis and formulation analysis studies

Independent monitoring may support in chemico, in vitro, and in vivo studies across pharmaceutical, veterinary pharmaceutical, chemical, medical device, food/feed, and cosmetic development programs.

The level of monitoring required depends on the study objectives, regulatory importance, complexity, and sponsor oversight needs.

Effective study monitoring can support the principles of Replacement, Reduction, and Refinement (3Rs) by helping ensure that toxicology studies are scientifically justified, appropriately designed, and conducted according to regulatory expectations.

Independent study monitoring does not replace the scientific assessment required to determine whether animal studies are necessary. However, it can help reduce unnecessary animal use by identifying opportunities to improve study design, avoid repeat studies, and ensure that available data are appropriately considered before additional testing is initiated.

Study monitoring can support the 3Rs by:

• Reviewing study objectives and designs to ensure that testing strategies are scientifically appropriate
• Identifying potential issues early to reduce the likelihood of repeat studies
• Supporting the use of New Approach Methodologies (NAMs), including in vitro and in silico approaches, where scientifically and regulatorily appropriate
• Supporting Integrated Approaches to Testing and Assessment (IATA) and weight-of-evidence strategies
• Ensuring that study data are adequately documented and interpreted for regulatory decision-making

By improving study planning, oversight, and data quality, independent monitoring can contribute to more efficient toxicology programs while supporting responsible use of animals in research and regulatory testing.

A toxicology study generates a series of scientific and regulatory deliverables that support interpretation of study results and regulatory evaluation. These deliverables provide evidence that the study was appropriately designed, conducted according to applicable requirements, and adequately documented.

Key toxicology study deliverables typically include:

• Study protocol and approved amendments
• Study plans, procedures, and relevant documentation
• Raw data and study records
• Quality assurance documentation and audit information, where applicable
• Protocol deviation records and corrective action documentation
• Statistical analyses and data interpretation
• Interim study updates or reports, where applicable
• Final study report

For regulatory submissions, the final study report is a critical deliverable because it summarizes the study design, methods, results, interpretation, and compliance with applicable standards such as Good Laboratory Practice (GLP) and relevant regulatory guidelines.

Independent study monitoring supports the quality of these deliverables by reviewing study documentation, assessing data consistency, identifying potential issues, and helping ensure that study outputs are complete, traceable, scientifically justified, and suitable for regulatory submission.

Independent scientific and regulatory oversight is available for outsourced non-clinical studies across pharmaceutical, veterinary pharmaceutical, chemical, medical device, food/feed, and cosmetic development programs. The objective is to help sponsors maintain visibility of CRO activities, identify potential risks early, and ensure the generation of reliable data suitable for regulatory evaluation.